Autoimmunity-blocking Antibody for Tolerance in Recently Diagnosed Type 1 Diabetes

(

AbATE

)

ITN Protocol #:

ITN027AI

Branded Name:

AbATE

ClinicalTrials.Gov ID:

NCT00129259

Treatment Protocol #:

hOKT3g1

Therapeutic Area:

Type 1 Diabetes

Current Status:

Complete

ITN Website Clinical Trial Recruiting Site Document Portal Location Study on ITN TrialShare

Summary:

Phase ll Multiple Dose Treatment of Type 1 Diabetes Mellitus with hOKT3y1 (Ala-Ala)

Clinical Operations Manager

ITN Biostat

ITN Clinical Trial Physician

NIAID Project Manager

Rho Data Manager

Rho Scientist

Study Personnel:

Protocol Chair

Kevan Herold, MD kevan.herold@yale.edu

Work:

203-785-6507

Protocol Chair

Carol Soppe csoppe@immunetolerance.org

Work:

415-353-4879

Protocol Chair

Noha Lim, PhD nlim@immunetolerance.org

Work:

240-235-6151

Protocol Chair

Srinath Sanda, MD ssanda@immunetolerance.org

Work:

415-353-4414

Protocol Chair

Peggy Fitzgibbon peggy.fitzgibbon@nih.gov

Work:

240-627-3505

Protocol Chair

LaSonia Morgan LaSonia_Morgan@rhoworld.com

Work:

919-595-6379

Protocol Chair

Karen Boyle Karen_Boyle@rhoworld.com

Work:

919-595-6375

Admin Links

Shortcuts

ITN Documents

Links